Frontotemporal Dementia (FTD) — Deal Benchmarks & Valuation
Market Analysis
Frontotemporal Dementia (FTD) is one of the most actively transacted indications in neurology licensing. Phase 1 deals for frontotemporal dementia (ftd) carry a median total deal value of $1.6B, with upfront payments ranging from $45M to $184M. The recommended deal structure allocates approximately 7% to upfront payments and 93% to milestones.
Milestone structures for frontotemporal dementia (ftd) deals allocate $750M to development milestones, $450M to regulatory milestones, and $300M to commercial milestones. Royalty rates range from 7.4% to 14.8% at the base tier, with tiered escalation reaching 11.4%-18.8% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for frontotemporal dementia (ftd) licensing?
What royalty rates are standard for frontotemporal dementia (ftd) deals?
How are frontotemporal dementia (ftd) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.